A comprehensive review of urologic complications in patients with diabetes

Fernando Arrellano-Valdez, Marta Urrutia-Osorio, Carlos Arroyo, Elena Soto-Vega, Fernando Arrellano-Valdez, Marta Urrutia-Osorio, Carlos Arroyo, Elena Soto-Vega

Abstract

Diabetes Mellitus (DM) is a chronic disease characterized by hyperglycemia, as a result of abnormal insulin production, insulin function, or both. DM is associated with systemic complications, such as infections, neuropathy and angiopathy, which involve the genitourinary tract. The three most significant urologic complications include: bladder cystopathy, sexual dysfunction and urinary tract infections. Almost half of the patients with DM have bladder dysfunction or cystopathy, which can be manifested in women as hypersensitivity (in 39-61% of the diabetic women) or neurogenic bladder. In males it can be experienced as lower urinary tract symptoms (in 25% of diabetic males with a nearly twofold increased risk when seen by age groups). Additionally, an increased prostate volume affects their micturition as well as their urinary tract. Involving sexual dysfunction in women, it includes reduced libido, decreased arousal, clitoral erectile dysfunction and painful or non-sensitive intercourse; and in diabetic males it varies from low libido, ejaculatory abnormalities and erectile dysfunction. Globally, sexual disorders have a prevalence of 18-42%. Erectile dysfunction is ranked as the third most important complication of DM. Urinary tract infections are observed frequently in diabetic patients, and vary from emphysematous infections, Fournier gangrene, staghorn infected lithiasis to repetitive bacterial cystitis. The most frequent finding in diabetic women has been lower urinary tract infections. Because of the high incidence of obesity worldwide and its association with diabetes, it is very important to keep in mind the urologic complication associated with DM in patients, in order to better diagnose and treat this population.

Keywords: Diabetes mellitus; Urologic diseases.

References

    1. Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel b3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012;62:1165–73. doi: 10.1016/j.eururo.2012.08.056.
    1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(1):S62–S69. doi: 10.2337/dc11-S062.
    1. Basu A, Ryder RE. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs. 2004;64(23):2667–2688. doi: 10.2165/00003495-200464230-00004.
    1. Berger P, Deibl M, Halpern EJ, Lechleitner M, Bektic J, Horninger W, Fritsche G, Steiner H, Pelzer A, Bartsch G, Frauscher F. Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. Diabetologia. 2005;48:784–789. doi: 10.1007/s00125-005-1678-6.
    1. Beshay E, Carrier S. Oxidative stress plays a role in diabetes-induced bladder dysfunction in a rat model. Urology. 2004;64:1062. doi: 10.1016/j.urology.2004.06.021.
    1. Bittencourt JA, Tano T, Gajar SA, Resende AC, de Lemos NM, Damião R, Criddle DN, de Bem GF, de Moura RS. Relaxant effects of sildenafil on the human isolated bladder neck. Urology. 2009;73(2):427–30. doi: 10.1016/j.urology.2008.06.060.
    1. Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, Champion HC. Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic- associated erectile dysfunction. Biochem Biophys Res Commun. 2001;283:923–927. doi: 10.1006/bbrc.2001.4874.
    1. Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia. 2001;44:1296–1301. doi: 10.1007/s001250100656.
    1. Boyko EJ, Fihn SD, Scholes D, Chen CL, Normand EH, Yarbro P. Diabetes and the risk of acute urinary tract infection among postmenopausal women. Diabetes Care. 2002;25:1778–1783. doi: 10.2337/diacare.25.10.1778.
    1. Brown JS, Nyberg LM, Kusek JW, Diokno AC, Foldspang FNH, Herzog AR, Hunskarr S, Milsom I, Nygaard I, Subak LL, Thom DH. Proceedings of the National Institute of Diabetes and Digestive and Kidney Diseases International Symposium on epidemiologic issues in urinary incontinence in women. Am J Obstet Gynecol. 2003;188:S77–88. doi: 10.1067/mob.2003.353.
    1. Brown JS, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, Ma Y. Incontinence in women with impaired glucose tolerance: results of the Diabetes Prevention Program. J Urol. 2004;171:325–326. doi: 10.1097/01.ju.0000117962.54732.3e.
    1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820. doi: 10.1038/414813a.
    1. Burchardt T, Burchardt M, Karden J, Buttyan R, Shabsigh A, de la Taille A, Ng PY, Anastasiadis AG, Shabsigh R. Reduction of endothelial and smooth muscle density in the corpora cavernosa of the streptozotocin induced diabetic rat. J Urol. 2000;164:1807–1811. doi: 10.1016/S0022-5347(05)67111-X.
    1. Caqueiro J, Casqueiro J, ALves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab. 2012;16(Suppl1):S27–S36.
    1. Carson CC. Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. Curr Urol Rep. 2003;4:488–496. doi: 10.1007/s11934-003-0031-1.
    1. Cartledge JJ, Eardley I, Morrison JF. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int. 2001;87:402–407. doi: 10.1046/j.1464-410x.2001.00067.x.
    1. Changolkar AK, Hypolite JA, Disanto M, Oates PJ, Wein AJ, Chacko S. Diabetes induced decrease in detrusor smooth muscle force is associated with oxidative stress and overactivity of aldose reductase. J Urol. 2005;173:309–313. doi: 10.1097/01.ju.0000141583.31183.7a.
    1. Chapple C, Nitti V, Khullar V, Wyndaele J, Herschom S, Van Kerrebroeck P, Beth M, Siddiqui E. World J Urol. 2014. Onset of action of the b3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder.
    1. Cheng JT, Yu BC, Tong YC. Changes of M3-muscarinic receptor protein and mRNA expressions in the bladder urothelium and muscle layer of streptozotocininduced diabetic rats. Neurosci Lett. 2007;423:1–5. doi: 10.1016/j.neulet.2007.05.062.
    1. Chitaley K, Wingard CJ, Clinton Webb R, Branam H, Stopper VS, Lewis RW, Mills TM. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med. 2001;7:119–122. doi: 10.1038/83258.
    1. Dalal S, Nicolle L, Marrs CF, Zhang L, Harding G, Foxman B. Long-term escherichia coli asymptomatic bacteriuria among women with diabetes mellitus. Clin Infect Dis. 2009;49(4):491–497. doi: 10.1086/600883.
    1. Daneshgari F, Liu G, Birder L, Hanna-Mitchell AT, Chacko S. Diabetic bladder dysfunction: current translational knowledge. J Urol. 2009;182:S18–S26. doi: 10.1016/j.juro.2009.08.070.
    1. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005;32(4):379–v. doi: 10.1016/j.ucl.2005.08.007.
    1. Deli G, Bonsbyak E, Pusch G, Komoly S, Feher G. Diabetic neuropathies:diagnosis and management. Neuroendocrinol. 2013;98(4):267.280. doi: 10.1159/000358728.
    1. Doruk H, Akbay E, Çayan S, Akbay E, Bozlu M, Acar D. Effect of diabetes mellitus on female sexual function and risk factors. Arch Androl. 2005;51(1):1–6. doi: 10.1080/014850190512798.
    1. Enzlin P, Mathieu C, Van den Bruel A, Bosteels J, Vanderschueren D, Demyttenaere K. Sexual dysfunction in women with type 1 diabetes: a controlled study. Diabetes Care. 2002;25:672–677. doi: 10.2337/diacare.25.4.672.
    1. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem. 2008;114(1):23–37. doi: 10.1080/13813450801969715.
    1. Fulgham PF, Cochran JS, Denman JL, Feagins BA, Gross MB, Kadesky KT, Kadesky MC, Clark AR, Roehrborn CG. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol. 1998;160:2041–2046. doi: 10.1016/S0022-5347(01)62238-9.
    1. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet TJ, Hoepelman AI. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care. 2000;23:1737–1741. doi: 10.2337/diacare.23.12.1737.
    1. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Hoekstra JB, Bouter PK, Braveboer B, Collet TJ, Jansz AR, Hoepelman AM. Asymptomatic bacteriuria can be considered a diabetic complication in women with diabetes mellitus. Adv Exp Med Biol. 2000;485:309–314. doi: 10.1007/0-306-46840-9_41.
    1. Golbidi S, Laher I. Bladder dysfunction in diabetes mellitus. Front Pharmacol. 2010;1:136. doi: 10.3389/fphar.2010.00136.
    1. Grabe M, Bishop MC, Bjerklund-Johansen TE, Botto H, Cek M, Lobel B, Naber KG, Palou J, Tenke P, Wagenlehner F. Eur Assoc Urol. 2009. Guidelines on urological infections.
    1. Grant P, Jackson G, Baig I, Quin J. Erectile dysfunction in general medicine. Clin Med. 2013;13(2):136–40. doi: 10.7861/clinmedicine.13-2-136.
    1. Gray MA, Wang CC, Sacks MS, Yoshimura N, Chancellor M, Nagatomi J. Time dependent alterations of select genes in streptozotocin-induced diabetic rat bladder. Urology. 2008;71:1214–9. doi: 10.1016/j.urology.2007.11.054.
    1. Harding GK, Zhanel GG, Nicolle LE, Cheang M. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med. 2002;347:1576–1583. doi: 10.1056/NEJMoa021042.
    1. Heaton JP, Lording D, Liu SN, Litonjua AD, Guangwei L, Kim SC, Kim JJ, Zhi-Zhou S, Israr D, Niazi D, Rajatanavin R, Suyono S, Benard F, Casey R, Brock G, Belanger A. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res. 2001;13:317–321. doi: 10.1038/sj.ijir.3900760.
    1. Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. PT. 2013;38(7): 407:414–419.
    1. Ikeda K, Wada Y, Foster HE, Wang Z, Weiss RM, Latifpour J. Experimental diabetes-induced regression of the rat prostate is associated with an increased expression of transforming growth factor-beta. J Urol. 2000;164(1):180–185. doi: 10.1016/S0022-5347(05)67491-5.
    1. Jackson RA, Vittinghoff E, Kanaya AM, Resnick HE, Kritchevsky S, Miles T, Simonsick E, Brown JS. Aging and body composition. Obstet Gynecol. 2004;104:301–307. doi: 10.1097/01.AOG.0000133482.20685.d1.
    1. Kammerer-Doak D. The treatment of female sexual dysfunction. Int Urogynecol Assoc. 2012;7:1.
    1. Kebapci N, Yenilmez A, Efe B, Entok E, Demirustu C. Bladder dysfunction in type 2 diabetic patients. Neurourol Urodyn. 2007;26(6):814–819. doi: 10.1002/nau.20422.
    1. Latini DM, Penson DF, Lubeck DP, Wallace KL, Henning JM, Lue TF. Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction study. J Urol. 2003;169:1437–1442. doi: 10.1097/01.ju.0000049203.33463.9e.
    1. Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am. 2001;28:335–341. doi: 10.1016/S0094-0143(05)70142-7.
    1. Liu JL. Does IGF-I stimulate pancreatic islet cell growth? Cell Biochem Biophys. 2007;48(2–3):115–25.
    1. Liu G, Daneshgari F. Temporal diabetes- and diuresis-induced remodeling of the urinary bladder in the rat. Am J Physiol Regul Integr Comp Physiol. 2006;291:R837. doi: 10.1152/ajpregu.00917.2005.
    1. McVary KT, Rathnau CH, McKenna KE. Sexual dysfunction in the diabetic BB/WOR rat: a role of central neuropathy. Am J Physiol. 1997;272:R259–R267.
    1. Mcvary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donell RF, Foster HE, Jr, Gonzalez CM, Kaplan SA, Penson DF, Ulchaker JC, Wei JT. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803. doi: 10.1016/j.juro.2011.01.074.
    1. Morano S. Pathophysiology of diabetic sexual dysfunction. J Endocrinol Invest. 2003;26(3 Suppl):65–9.
    1. Neves D. Advanced glycation end-products: a common pathway in diabetes and age-related erectile dysfunction. Free Radic Res. 2013;47(Suppl 1):49–69. doi: 10.3109/10715762.2013.821701.
    1. Owiredu WK, Amidu N, Alidu H, Sarpong C, Gyasi-Sarpong CK. Determinants of sexual dysfunction among clinically diagnosed diabetic patients. Reprod Biol Endocrinol. 2011;25:9:70.
    1. Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G. Diabetic impotence treated by intracavernosal injections: high treatment compliance and increasing dosage of vaso-active drugs. Eur Urol. 2001;40:398–402. doi: 10.1159/000049806.
    1. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. The Am J Med. 2002;113:14–19. doi: 10.1016/S0002-9343(02)01055-0.
    1. Rull JA, Aguilar-Salinas CA, Rojas R, Rios-Torres JM, Gómez-Pérez FJ, Olaiz G. Epidemiology of type 2 diabetes in Mexico. Arch Med Res. 2005;36(3):188–196. doi: 10.1016/j.arcmed.2005.01.006.
    1. Satriano J. Kidney growth, hypertrophy and the unifying mechanism of diabetic complications. Amino Acids. 2007;33:331–339. doi: 10.1007/s00726-007-0529-9.
    1. Seftel AD, Vaziri ND, Ni Z, Razmjouei K, Fogarty J, Hampel N, Polak J, Wang RZ, Ferguson K, Block C, Haas C. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology. 1997;50(6):1016–1026. doi: 10.1016/S0090-4295(97)00512-8.
    1. Stapleton A. Urinary tract infections in patients with diabetes. Am J Med. 2002;113(suppl 1A):80S–84S. doi: 10.1016/S0002-9343(02)01062-8.
    1. Sun P, Cameron A, Seftel A, Shabsigh R, Niederberger C, Guay A. Erectile dysfunction-an observable marker of diabetes mellitus? a large national epidemiological study. J Urol. 2007;117. 4:1588.
    1. Torimoto K, Fraser MO, Hirao Y, De Groat WC, Chancellor MB, Yoshimura N. Urethral dysfunction in diabetic rats. J Urol. 2004;171:1959–64. doi: 10.1097/01.ju.0000121283.92963.05.
    1. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986;5(10):2503–2512.
    1. Vickers MA, Wright EA. Erectile dysfunction in the patient with diabetes mellitus. The Am J Managed Care. 2004;10:5–11.
    1. Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hiperplasia. Prostate. 2010;1;70(1):79–89. doi: 10.1002/pros.21041.
    1. Wei-Chia L. The impact of diabetes on the lower urinary tract dysfunction. JTUA. 2009;20:155–61.
    1. Yono M, Poursermail M, Takahashi W, Flanagan JF, Weiss RM, Latifpour J. Effect of insulin treatment on tissue size of the genitourinary tract in BB rats with spontaneously developed and streptozotocin-induced diabetes. Naunyn Schmiedebergs Arch Pharmacol. 2005;372(3):251–255. doi: 10.1007/s00210-005-0010-9.
    1. Yono M, Mane SM, Lin A, Weiss RM, Latifpour J. Differential effects of diabetes induced by streptozotocin and that develops spontaneously on prostate growth in Bio Breeding (BB) rats. Life Sci. 2008;83(5-6):192–197. doi: 10.1016/j.lfs.2008.06.006.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner